Jasper Therapeutics (JSPR) Competitors $2.40 -0.14 (-5.51%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$2.50 +0.10 (+4.17%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. NLTX, NVCT, CRBU, GNLX, CLYM, BTMD, GLSI, AVTX, ACTU, and MCRBShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Neoleukin Therapeutics (NLTX), Nuvectis Pharma (NVCT), Caribou Biosciences (CRBU), Genelux (GNLX), Climb Bio (CLYM), biote (BTMD), Greenwich LifeSciences (GLSI), Avalo Therapeutics (AVTX), Actuate Therapeutics (ACTU), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors Neoleukin Therapeutics Nuvectis Pharma Caribou Biosciences Genelux Climb Bio biote Greenwich LifeSciences Avalo Therapeutics Actuate Therapeutics Seres Therapeutics Neoleukin Therapeutics (NASDAQ:NLTX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Which has more risk and volatility, NLTX or JSPR? Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Does the media prefer NLTX or JSPR? In the previous week, Jasper Therapeutics had 26 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 26 mentions for Jasper Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Jasper Therapeutics' score of -0.19 indicating that Neoleukin Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neoleukin Therapeutics Neutral Jasper Therapeutics Neutral Which has preferable earnings and valuation, NLTX or JSPR? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.46Jasper TherapeuticsN/AN/A-$71.27M-$6.01-0.40 Is NLTX or JSPR more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Jasper Therapeutics N/A -172.28%-128.34% Do institutionals and insiders have more ownership in NLTX or JSPR? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer NLTX or JSPR? Jasper Therapeutics has a consensus target price of $25.63, indicating a potential upside of 967.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryJasper Therapeutics beats Neoleukin Therapeutics on 8 of the 13 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.28M$3.16B$5.76B$10.50BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-0.4021.0476.0426.62Price / SalesN/A252.06469.4291.51Price / CashN/A46.3537.4661.85Price / Book0.589.7813.676.45Net Income-$71.27M-$52.73M$3.29B$271.57M7 Day Performance3.00%3.16%1.83%2.61%1 Month Performance-18.09%4.69%3.98%7.28%1 Year Performance-88.99%16.37%78.13%29.60% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics3.2939 of 5 stars$2.40-5.5%$25.63+967.7%-88.9%$41.28MN/A-0.4020Trending NewsAnalyst ForecastNLTXNeoleukin TherapeuticsN/A$17.20-7.9%N/A-58.3%$161.65MN/A-5.5390High Trading VolumeNVCTNuvectis Pharma2.2813 of 5 stars$6.43+2.6%$15.33+138.5%-7.0%$159.61MN/A-5.508Positive NewsCRBUCaribou Biosciences2.0736 of 5 stars$1.93+14.2%$6.67+245.4%-2.1%$157.38M$9.99M-1.08100News CoveragePositive NewsGNLXGenelux0.9813 of 5 stars$4.11-1.2%$20.33+394.7%+101.9%$157.14M$10K-4.7810CLYMClimb Bio3.4891 of 5 stars$2.32+0.4%$9.00+287.9%N/A$156.54MN/A-3.319Positive NewsAnalyst ForecastBTMDbiote2.8597 of 5 stars$3.22+1.9%$6.00+86.3%-48.6%$156.23M$197.19M3.58194News CoveragePositive NewsGLSIGreenwich LifeSciences1.4296 of 5 stars$11.80+3.0%$42.00+255.9%-24.8%$156.20MN/A-8.683AVTXAvalo Therapeutics3.9522 of 5 stars$11.70-1.1%$31.67+170.7%+16.3%$155.59M$440K0.0040ACTUActuate Therapeutics2.4619 of 5 stars$7.09+6.8%$20.33+186.8%+3.3%$154.34MN/A0.0010Analyst ForecastMCRBSeres Therapeutics3.3385 of 5 stars$16.52-5.3%$73.67+345.9%-24.3%$152.77M$126.32M-3.59330News Coverage Related Companies and Tools Related Companies Neoleukin Therapeutics Alternatives Nuvectis Pharma Alternatives Caribou Biosciences Alternatives Genelux Alternatives Climb Bio Alternatives biote Alternatives Greenwich LifeSciences Alternatives Avalo Therapeutics Alternatives Actuate Therapeutics Alternatives Seres Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
